Results (3613)
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
EMA and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have signed a working arrangement with the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for the exchange of confidential information on medical and medicinal products.
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.
EMA has published a number of recommendations to address vulnerabilities in the production and delivery of medicines included in the Union list of critical medicines and strengthen their supply chain.
Report on COVID-19 vaccine strain updates: global regulators agree on timing and data requirements
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions
Due to planned system maintenance, several EMA applications will be fully or partially inaccessible from 11 to 17 April.
The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.
The European Medicines Agency's (EMA) office is closed from 18:30 on Wednesday 27 March 2024 to 07:30 on Tuesday 2 April 2024. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600.
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.